investig
impact
inflammatori
bowel
diseas
ibd
glycoprotein
ahsgfetuin
potenti
associ
diseas
patient
characterist
ahsg
serum
level
determin
newlydiagnos
patient
ulcer
coliti
uc
crohn
diseas
cd
diarrheapredomin
mix
irrit
bowel
syndrom
ib
dand
mtype
healthi
control
hc
enzym
link
immunosorb
assay
elisa
patient
follow
minimum
period
year
gastroenterolog
depart
univers
hospit
larissa
greec
creactiv
protein
crp
antiglycan
antibodi
antisaccharomyc
cerevisia
mannan
antibodi
igg
antimannobiosid
carbohydr
antibodi
igg
antilaminariobiosid
carbohydr
antibodi
igg
antichitobiosid
carbohydr
antibodi
iga
also
determin
via
immunonephelometri
elisa
respect
mean
se
serum
ahsg
follow
adjust
confound
gl
ibd
gl
cd
gl
uc
patient
significantli
lower
ib
patient
gl
hc
gl
p
case
ahsg
level
compar
cd
uc
group
base
ahsg
level
ibd
patient
could
distinguish
hc
sensit
specif
adjust
analysi
verifi
invers
associ
ahsg
penetr
well
strictur
cd
partial
correl
coeffici
respect
p
adjust
confound
factor
invers
correl
ahsg
crp
need
therapi
surgeri
found
partial
correl
coeffici
respect
p
case
final
ibd
individu
seroposit
least
one
marker
ahsg
level
fall
within
two
lower
quartil
ci
p
least
two
serolog
marker
posit
exhibit
ahsg
concentr
within
lowest
quartil
ci
p
adjust
age
sex
smoke
ahsg
use
distinguish
ibd
ib
patient
hc
time
predict
complic
diseas
behavior
need
therapi
escal
surgeri
moreov
ahsg
may
offer
new
insight
pathogenesi
ibd
sinc
involv
key
process
inflammatori
bowel
diseas
ibd
long
ago
recogn
system
inflammatori
entiti
anticip
induc
chang
exceed
boundari
bowel
mucosa
reflect
broader
spectrum
tissu
includ
blood
exampl
chang
fluctuat
level
creactiv
protein
crp
tumour
necrosi
factor
alpha
interleukin
protein
metalloproteinas
angiogenin
etc
sinc
differ
task
carri
biomark
propos
ibd
induc
multifari
respons
turn
may
affect
level
differ
compound
via
feedback
mechan
consumpt
reprioritis
synthesi
observ
along
inflammatori
natur
ibd
seem
encourag
studi
novel
protein
tend
becom
affect
establish
system
inflamm
candid
fetuin
glycoprotein
ahsg
substanc
synthes
liver
bone
marrow
fetal
organ
exhibit
properti
similar
possess
neg
acutephas
protein
ahsg
shown
carri
variou
immunolog
task
includ
regul
macrophagerel
lipopolysaccharidetrigg
opsonis
transform
growth
factor
beta
level
ahsg
also
inhibitor
ectop
tissu
calcif
take
place
coronari
arteri
heart
valv
time
promot
miner
within
fibril
subsequ
proper
bone
format
recent
discov
properti
ahsg
includ
bind
abil
insulin
receptor
modifi
sensit
particip
wound
heal
well
tumor
growth
process
induct
effect
cell
migrat
increas
ahsg
level
record
fetal
organ
probabl
reflect
addit
role
ahsg
normal
organ
develop
adult
either
metabol
syndrom
increas
insulin
resist
alon
patient
infect
sever
acut
respiratori
syndromecoronaviru
well
individu
high
risk
futur
cardiovascular
event
stroke
acut
myocardi
infarct
low
level
ahsg
record
patient
hemodialysi
cirrhosi
hepatoma
rheumatoid
arthriti
ra
entiti
share
common
inflammatori
pathway
ibd
link
vascular
excess
valvular
coronari
arteri
calcif
ischem
eventsand
skelet
disord
osteopenia
moreov
similar
phenomena
upregul
remodel
intestin
microvessel
acut
chronic
basi
well
manifest
link
miner
homeostasi
ie
osteoporosi
urolithiasi
exert
ibd
bear
mind
characterist
idea
examin
ahsg
level
ibd
seem
tempt
among
sever
patient
visit
er
ward
outpati
clinic
hospitalis
chronic
diarrhea
total
patient
recruit
diagnos
ulcer
coliti
uc
crohn
diseas
cd
irrit
bowel
syndrom
ib
patient
follow
minimum
period
year
depart
gastroenterolog
univers
hospit
larissa
greec
anoth
group
consist
healthi
individu
also
form
hc
studi
group
age
sex
match
p
one
except
cd
uc
group
differ
significantli
p
anticip
sinc
cd
often
associ
younger
age
individu
particip
studi
lack
known
diseas
ie
endstag
renal
diseas
ra
cirrhosi
hepatoma
liver
metastas
potenti
affect
ahsg
level
except
diabet
mellitu
dm
treat
confound
factor
embed
model
use
multivari
test
demograph
clinic
characterist
patient
hc
present
tabl
diagnosi
ibd
ib
establish
upon
coevalu
find
origin
clinic
endoscop
procedur
imag
studi
histopatholog
laboratori
analys
ib
patient
also
diagnos
classifi
dib
mib
individu
respect
accord
rome
criteria
diseas
activ
ibd
group
document
use
convent
indic
crohn
diseas
activ
index
cdai
clinic
activ
index
cai
uc
cdai
score
greater
januari
wjgwwwwjgnetcom
cai
score
exceed
scale
consid
activ
cd
activ
uc
respect
diseas
locat
behavior
cd
determin
use
vienna
classif
wherea
diseas
extent
uc
montreal
classif
use
anim
use
present
studi
blood
sampl
collect
upon
present
patient
hospit
serum
separ
tube
allow
clot
min
sampl
centrifug
obtain
serum
store
later
analysi
preanalyt
phase
includ
sampl
handl
method
sampl
tube
storag
condit
etc
ident
case
ahsg
assay
ahsg
determin
twosit
sandwich
enzymelink
immunosorb
assay
elisa
perform
use
commerci
avail
human
fetuin
elisa
kit
biosourc
europ
sa
belgium
assay
calibr
control
predilut
patient
serum
sampl
initi
contain
human
ahsg
ad
micropl
well
coat
high
affin
polyclon
goat
antihuman
ahsg
antibodi
incub
period
antibodi
could
captur
human
ahsg
sampl
unbound
protein
wash
away
horseradish
peroxidas
hrp
conjug
polyclon
antihuman
ahsg
antibodi
ad
well
sandwich
captur
antibodyhuman
ahsghrp
conjug
detect
antibodi
could
form
addit
wash
incub
substrat
solut
took
place
reaction
stop
develop
colour
quantifi
spectrophotometr
enzymat
activ
detect
antibodi
bound
ahsg
wall
microwel
directli
proport
amount
ahsg
sampl
calibr
curv
gener
plot
absorb
vs
respect
human
ahsg
concentr
calibr
allow
sampl
ahsg
determin
creactiv
protein
assay
determin
creactiv
protein
crp
immunonephelometri
perform
use
behr
nephelomet
analyz
well
n
high
sensit
commerci
avail
kit
dade
behr
gmbh
germani
control
standard
sera
provid
compani
use
accord
manufactur
instruct
antiglycan
antibodi
assay
serum
level
antisaccharomyc
cerevisia
mannan
antibodi
gasca
igg
antimannobiosid
carbohydr
antibodi
amca
igg
antilaminariobiosid
carbohydr
antibodi
alca
igg
antichitobiosid
carbohydr
antibodi
acca
iga
also
determin
ibd
cd
uc
patient
use
commerci
avail
elisa
kit
ibdx
glycomind
ltd
israel
cutoff
level
posit
set
uml
gasca
igg
amca
igg
alca
igg
acca
iga
respect
instruct
manufactur
normal
kolmogorovsmirnov
test
initi
carri
sinc
normal
assumpt
satisfi
comparison
mean
two
group
student
ttest
use
comparison
multipl
group
oneway
anova
tukey
posthoc
test
appli
variabl
express
mean
sd
mean
se
variabl
without
compar
variat
welch
correct
appli
ahsg
test
abil
predict
ibd
uc
cd
separ
use
receiv
oper
characterist
roc
curv
area
curv
auc
cutoff
valu
optim
sensit
specif
also
calcul
simpl
correl
studi
pearson
rank
test
use
statist
signific
set
p
whenev
statist
signific
trend
p
record
univari
analysi
multivari
test
also
perform
use
multipl
linear
regress
backward
select
process
independ
variabl
affect
ahsg
level
confound
identifi
candid
confound
factor
initi
consid
age
sex
smoke
dm
treatment
modal
diseas
durat
behaviour
age
onset
associ
origin
multipl
linear
regress
partial
correl
coeffici
quantifi
relationship
two
variabl
control
factorsar
report
whenev
categor
paramet
treat
depend
variabl
logist
regress
analys
simpl
multipl
appli
odd
ratio
or
well
ci
unadjustedadjust
confound
calcul
adjust
mean
also
calcul
use
analysi
covari
statist
analys
conduct
use
graphpad
prism
medcalc
statist
softwar
statist
review
studi
perform
biostatistician
studi
approv
univers
thessali
medic
school
ethic
committe
inform
consent
obtain
studi
particip
along
verbal
permiss
use
acquir
sampl
scientif
research
mean
se
ahsg
serum
gl
ibd
gl
ib
patient
gl
hc
record
differ
ibd
control
group
statist
signific
p
also
case
cd
uc
compar
separ
ib
patient
hc
ahsg
level
cd
group
gl
significantli
lower
ib
patient
hc
p
likewis
uc
patient
also
exhibit
lower
ahsg
level
gl
compar
ib
patient
hc
p
differ
remain
signific
ibd
gl
cd
gl
uc
patient
gl
ib
patient
gl
hc
gl
adjust
age
sex
p
comparison
ahsg
level
compar
uc
cd
patient
ib
patient
hc
signific
differ
observ
p
case
figur
roc
curv
analysi
show
optim
cutoff
ahsg
predict
ibd
gl
sensit
specif
similarli
ahsg
valu
gl
could
distinguish
cd
patient
nonibd
individu
ib
hc
sensit
specif
valu
gl
could
discrimin
uc
patient
nonibd
subject
sensit
specif
auc
ci
ci
ci
predict
ibd
uc
cd
respect
p
case
figur
ibd
patient
exhibit
activ
diseas
blood
drawn
later
analysi
studi
patient
activ
diseas
ahsg
level
margin
associ
cdai
cai
score
r
p
diseas
locat
cd
extent
uc
taken
consider
statist
signific
differ
observ
p
case
anoth
part
present
studi
includ
comparison
ahsg
serum
concentr
among
cd
patient
divers
diseas
behavior
strictur
penetr
nonstrictur
nonpenetr
nsnp
perform
analysi
show
patient
strictur
penetr
diseas
lower
ahsg
level
gl
gl
respect
compar
patient
nsnp
subgroup
gl
differ
statist
signific
cd
patient
strictur
nsnp
p
penetr
nsnp
diseas
subgroup
p
strictur
penetr
subgroup
p
figur
analysi
verifi
invers
associ
ahsg
penetr
well
strictur
cd
r
respect
p
well
adjust
partial
correl
coeffici
respect
p
age
sex
smoke
statu
order
perform
addit
test
link
lower
ahsg
level
complic
diseas
behavior
logist
regress
appli
consid
penetr
strictur
cd
depend
ahsg
concentr
quartil
lowest
low
high
highest
independ
variabl
result
origin
analysi
show
ahsg
level
lowest
quartil
associ
penetr
well
strictur
diseas
ci
ci
respect
adjust
ci
ci
respect
age
sex
smoke
statu
p
case
ahsg
level
also
examin
respect
presenc
one
ibdrel
extraintestin
manifest
ibd
patient
exhibit
extraintestin
manifest
compar
ahsg
level
gl
ibd
subgroup
without
disord
gl
p
interestingli
ibd
patient
histori
recurr
urolithiasi
ahsg
level
lowest
quartil
result
howev
reach
statist
signific
data
ahsg
variat
accord
alreadi
describ
diseas
characterist
present
tabl
level
serum
ahsg
studi
respect
gender
ibd
patient
potenti
differ
could
highlight
male
femal
ibd
patient
exhibit
compar
ahsg
level
gl
gl
respect
p
likewis
ahsg
level
similar
ibd
patient
take
account
age
onset
smoke
habit
tabl
serum
ahsg
concentr
examin
regard
treatment
modal
adequ
induc
maintain
remiss
follow
period
corticosteroid
immunosuppress
agent
surgeri
comparison
ibd
patient
requir
surgic
intervent
use
therapi
exhibit
lower
ahsg
concentr
gl
gl
compar
adequ
treat
gl
corticosteroid
gl
p
case
evalu
record
associ
use
simpl
linear
regress
analysi
show
ahsg
level
invers
associ
need
treatment
r
p
surgeri
r
p
multivari
analysi
also
consid
age
sex
activ
durat
smoke
statusth
invers
associ
ahsg
need
therapi
surgeri
remain
statist
signific
partial
correl
coeffici
respect
p
case
sinc
result
suggest
link
profound
downregul
ahsg
level
need
treatment
surgic
intervent
ahsg
concentr
classifi
quartil
use
logist
regress
ahsg
level
lowest
quartil
found
independ
predictor
need
treatment
model
adjust
treatment
modal
age
sex
smoke
statu
diseas
durat
ci
p
similarli
appli
adjust
model
shown
need
surgeri
could
independ
predict
presenc
ahsg
level
within
lowest
quartil
ci
p
ibd
patient
higher
crp
level
median
mgdl
rang
mgdl
compar
ib
median
mgdl
rang
mgdl
hc
group
median
mgdl
rang
mgdl
p
correl
studi
ahsg
level
inflammatori
marker
crp
perform
reveal
margin
associ
r
p
multivari
analysi
consid
confound
variabl
age
sex
smoke
hand
reveal
closer
associ
two
substanc
partial
correl
coeffici
p
level
signific
posit
rate
serolog
marker
gasca
alca
amca
alca
actual
median
concentr
present
tabl
addit
associ
investig
examin
posit
serolog
marker
januari
wjgwwwwjgnetcom
ahsg
quartil
interestingli
invers
associ
serolog
ahsg
level
record
ibd
individu
seroposit
least
one
marker
ahsg
level
fall
within
two
lower
quartil
ci
p
least
two
serolog
marker
posit
exhibit
ahsg
concentr
within
lowest
quartil
ci
p
analysi
also
consid
potenti
confound
factor
age
sex
smoke
alter
report
associ
significantli
ci
singl
ci
multipl
seroposit
p
case
accord
preliminari
report
team
ahsg
level
downregul
patient
ibd
thu
allow
discrimin
ib
hc
individu
furthermor
profound
downregul
ahsg
well
associ
complic
diseas
behavior
need
biolog
treatment
surgeri
addit
associ
crp
antiglycan
antibodi
offer
better
insight
ahsg
link
acutephas
respons
januari
wjgwwwwjgnetcom
ibd
cours
find
ibdinduc
downregul
ahsg
noth
surpris
sinc
ahsg
level
decreas
presenc
robust
inflamm
moreov
interplay
alreadi
document
ahsg
notori
ibd
addit
find
confirm
tight
link
ahsg
discoveri
bind
site
within
ahsg
gene
consequ
bind
region
express
ahsg
gene
suppress
lead
decreas
ahsg
product
substanc
favoredreprioris
liver
synthesi
due
magnitud
rather
ibdselect
charact
suppress
howev
evalu
ahsg
abil
differenti
entiti
perform
cutoff
gl
use
ahsg
level
shown
discrimin
ibd
ib
hc
sensit
specif
magnitud
diseas
activ
express
cdai
cai
score
taken
consider
margin
differ
detect
accord
studi
et
al
signific
differ
ahsg
level
exist
ibd
patient
activ
inact
diseas
hand
correl
ahsg
crp
confirm
studi
may
least
part
due
limit
indic
although
one
bear
mind
apart
neg
acut
phase
protein
properti
attribut
ahsg
downregul
also
part
complex
liver
deregul
result
excess
uptak
process
signal
perhap
possibl
associ
ahsg
indic
also
evalu
point
howev
asset
present
studi
underlin
ahsg
level
record
ibd
patient
correspond
priortotherapi
statu
therefor
could
alter
known
drug
use
treat
ibd
differ
set
result
obtain
examin
ahsg
level
respect
uc
extent
cd
locat
record
ahsg
level
studi
could
predict
diseas
locat
extent
therefor
could
use
purpos
case
diseas
behavior
taken
account
downregul
ahsg
observ
cd
patient
strictur
penetr
diseas
compar
nsnp
subtyp
surpris
diffus
transmur
inflamm
would
exert
stronger
proinflammatori
effect
moreov
mani
organ
inflammatori
stress
lead
fibrosi
subsequ
tissu
calcif
anoth
pathogenet
perspect
reason
observ
link
ahsg
strictur
diseas
could
also
reduc
ahsginduc
counteract
fibrogen
antiprolif
potenti
likewis
microvascular
calcif
reduc
blood
flow
microthrombosi
exert
phenomena
presenc
low
ahsg
level
also
major
find
chronic
phase
intestin
vasculatur
ibd
patient
lead
diminish
intestin
perfus
turn
ulcer
fibrosi
anoth
scopu
present
studi
test
whether
link
ahsg
level
presenc
extraintestin
manifest
perform
analysi
reveal
associ
ahsg
serum
concentr
presenc
extraintestin
manifest
case
limit
exist
rather
small
number
ibd
patient
manifest
specif
disord
ie
urolithiasi
studi
focus
characterist
ibd
patient
ahsg
level
also
perform
ahsg
concentr
compar
among
patient
differ
gender
smoke
statu
age
onset
none
characterist
male
femal
sex
current
smoke
nonsmok
habit
age
onsetcould
link
signific
ahsg
variat
case
ahsg
level
evalu
respect
treatment
modal
adequ
induc
sustain
diseas
remiss
threeyear
followup
period
robust
downregul
ahsg
level
correl
need
therapi
find
within
reason
sinc
profound
persist
upregul
requir
subsequ
use
agent
would
result
greater
ahsg
decreas
far
link
ahsg
level
need
surgeri
concern
one
also
bear
mind
subgroup
predominantli
consist
cd
patient
strictur
penetr
diseas
case
refractori
uc
requir
colectomi
safe
conclus
could
drawn
due
small
number
colectomis
patient
studi
evid
mention
seem
make
rather
appeal
idea
ahsg
use
diagnost
even
predict
tool
rather
tightli
link
ibd
behavior
well
marker
relat
antiglycan
antibodi
prerequisit
type
use
lack
diseasespecif
natur
similar
fluctuat
also
report
disord
taken
account
combin
clinic
ahsgbas
algorithm
diagnosi
ibd
hand
could
help
overcom
limit
set
asid
alreadyperform
diagnosticallyori
interpret
current
result
care
examin
ahsg
potenti
implic
pathogenesi
complic
ibd
also
perform
alreadi
mention
ahsg
inhibitor
unwant
ectop
tissu
calcif
decreas
level
case
link
excess
valvular
arteri
calcif
although
initi
report
origin
anim
studi
recruit
dialysi
patient
similar
result
obtain
patient
ischem
heart
diseas
alon
sinc
decreas
circul
ahsg
present
ibd
would
logic
hypothes
accompani
reduc
inhibit
vascular
valvular
calcif
would
also
present
studi
design
tackl
matter
actual
contribut
low
ahsg
level
vascular
chang
relat
acut
chronic
ischem
event
ibd
remain
clarifi
apart
implic
ahsg
vascular
patholog
anoth
role
bone
mineralis
identifi
influenc
ahsg
reliabl
stressresist
bone
structur
form
absenc
ahsg
miner
deposit
outsid
fibril
lead
defect
osseou
format
final
osteoporosi
ibd
patient
high
risk
osteoporosi
result
corticosteroid
malnutrit
inflammationinduc
osteopenia
examin
possibl
contribut
ahsg
suppress
onset
osteopen
manifest
might
prove
fruit
rather
similar
manner
defect
coordin
miner
use
predominantli
calcium
due
decreas
ahsg
level
may
lead
urolithiasi
inde
studi
stejskal
et
al
lower
level
ahsg
urin
associ
presenc
urolithiasi
although
case
ibd
wellestablish
mechanismsi
hyperoxaluria
reduc
citric
acid
etc
urinari
compic
exist
bear
mind
still
urinari
stone
consist
calcium
salt
within
reason
test
addit
candid
involv
calcium
homeostasi
urinari
manifest
ahsg
conclus
ahsg
seem
emerg
molecul
potenti
diagnost
perhap
predict
valu
ibd
downregul
show
tight
link
acutephas
well
chronic
inflammatori
respons
cd
uc
link
also
encompass
challeng
case
complic
diseas
behavior
well
requir
advanc
treatment
strategi
biolog
agent
surgeri
far
pathogenet
role
ahsg
ibd
concern
studi
design
assess
impact
associ
low
ahsg
level
respect
microand
macrovascular
chang
skelet
urinari
complic
record
patient
cd
uc
need
